ERBB2 and neoplasm: No statistically significant differences were observed between the two groups in terms of baseline characteristics, including age, lymph node status, tumor size, tumor grade, histology, human epidermal growth factor receptor 2 (HER2) status, chemotherapy regimen, and surgery or radiotherapy history, showing comparable cohorts after randomization (Table 1).